Neurocrine price target raised to $150 from $146 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Neurocrine Biosciences to $150 from $146 and keeps a Buy rating on the shares. The price target increase can be fully ascribed to the incorporation of crinecerfont into the model, the analyst tells investors in a research note. The analyst says adequate control on exogenous glucocorticoid and androgen levels “might translate into strong demand in pediatric settings.”